Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.06 is 1203% above its 1-year average of 0.00, near the high end of its 1-year range (-0.05–0.06).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to equity ratio; no daily interpolation.
Limited quarterly history available
Debt to Equity needs at least three reported quarters before a meaningful chart is shown.
DEBT TO EQUITY RATIO
0.06
DEBT TO EQUITY RATIO AVG TTM
N/A
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-46.42%
vs the sector median at left
Odyssey Therapeutics, Inc.
Market Cap
$876.57M
Debt to Equity Ratio
0.06
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$880.01M
Debt to Equity Ratio
0.00
TTM Avg
0.03
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$885.96M
Debt to Equity Ratio
0.01
TTM Avg
0.06
3Y Avg
0.07
5Y Avg
0.10
Market Cap
$869.18M
Debt to Equity Ratio
0.09
TTM Avg
0.04
3Y Avg
0.08
5Y Avg
0.08
Market Cap
$855.35M
Debt to Equity Ratio
0.09
TTM Avg
9.19
3Y Avg
9.19
5Y Avg
5.13
Market Cap
$851.60M
Debt to Equity Ratio
1.73
TTM Avg
1.19
3Y Avg
0.87
5Y Avg
0.60
Market Cap
$846.39M
Debt to Equity Ratio
N/A
TTM Avg
71.70
3Y Avg
36.60
5Y Avg
24.63
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Odyssey Therapeutics, Inc. (ODTX) | $876.57M | 0.06 | N/A | N/A | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $880.01M | 0.00 | 0.03 | 0.03 | 0.03 |
| Arbutus Biopharma Corp (ABUS)vs › | $885.96M | 0.01 | 0.06 | 0.07 | 0.10 |
| SL Science Holding Ltd (SLBT)vs › | $869.18M | 0.09 | 0.04 | 0.08 | 0.08 |
| Bioventus Inc. (BVS)vs › | $890.87M | 1.16 | 1.98 | 1.88 | 1.60 |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $855.35M | 0.09 | 9.19 | 9.19 | 5.13 |
| SI-BONE, Inc. (SIBN)vs › | $853.72M | 0.04 | 0.12 | 0.21 | 0.23 |
| QuidelOrtho Corporation (QDEL)vs › | $851.60M | 1.73 | 1.19 | 0.87 | 0.60 |
| Pacific Biosciences of California, Inc. (PACB)vs › | $846.39M | N/A | 71.70 | 36.60 | 24.63 |
| HealthStream, Inc. (HSTM)vs › | $910.05M | 0.04 | 0.05 | 0.06 | 0.07 |
Debt/Equity
0.06
Current Ratio
11.36
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.06 |
| 2026-03-31 | -0.05 |
